<?xml version='1.0' encoding='utf-8'?>
<document id="29129847"><sentence text="Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models."><entity charOffset="11-23" id="DDI-PubMed.29129847.s1.e0" text="ketoconazole" /><entity charOffset="27-43" id="DDI-PubMed.29129847.s1.e1" text="cyclophosphamide" /><pair ddi="false" e1="DDI-PubMed.29129847.s1.e0" e2="DDI-PubMed.29129847.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29129847.s1.e0" e2="DDI-PubMed.29129847.s1.e1" /></sentence><sentence text="Cyclophosphamide (CP) is widely used in anticancer therapy regimens and 2-dechloroethylcyclophosphamide (DECP) is its side-chain dechloroethylated metabolite"><entity charOffset="0-16" id="DDI-PubMed.29129847.s2.e0" text="Cyclophosphamide" /><entity charOffset="18-20" id="DDI-PubMed.29129847.s2.e1" text="CP" /><entity charOffset="72-103" id="DDI-PubMed.29129847.s2.e2" text="2-dechloroethylcyclophosphamide" /><entity charOffset="105-109" id="DDI-PubMed.29129847.s2.e3" text="DECP" /><entity charOffset="107-110" id="DDI-PubMed.29129847.s2.e4" text="CP" /><pair ddi="false" e1="DDI-PubMed.29129847.s2.e0" e2="DDI-PubMed.29129847.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29129847.s2.e0" e2="DDI-PubMed.29129847.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29129847.s2.e0" e2="DDI-PubMed.29129847.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29129847.s2.e0" e2="DDI-PubMed.29129847.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29129847.s2.e0" e2="DDI-PubMed.29129847.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29129847.s2.e1" e2="DDI-PubMed.29129847.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29129847.s2.e1" e2="DDI-PubMed.29129847.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29129847.s2.e1" e2="DDI-PubMed.29129847.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29129847.s2.e1" e2="DDI-PubMed.29129847.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29129847.s2.e2" e2="DDI-PubMed.29129847.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29129847.s2.e2" e2="DDI-PubMed.29129847.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29129847.s2.e2" e2="DDI-PubMed.29129847.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29129847.s2.e3" e2="DDI-PubMed.29129847.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29129847.s2.e3" e2="DDI-PubMed.29129847.s2.e4" /></sentence><sentence text=" N-dechloroethylation of CP mediated by the enzyme CYP3A4 yields nephrotoxic and neurotoxic chloroacetaldehyde (CAA) in equimolar amount to DECP"><entity charOffset="92-110" id="DDI-PubMed.29129847.s3.e0" text="chloroacetaldehyde" /><entity charOffset="25-42" id="DDI-PubMed.29129847.s3.e1" text="CP" /><entity charOffset="142-159" id="DDI-PubMed.29129847.s3.e2" text="CP" /><entity charOffset="140-157" id="DDI-PubMed.29129847.s3.e3" text="DECP" /><pair ddi="false" e1="DDI-PubMed.29129847.s3.e1" e2="DDI-PubMed.29129847.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29129847.s3.e1" e2="DDI-PubMed.29129847.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29129847.s3.e1" e2="DDI-PubMed.29129847.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29129847.s3.e1" e2="DDI-PubMed.29129847.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29129847.s3.e0" e2="DDI-PubMed.29129847.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29129847.s3.e0" e2="DDI-PubMed.29129847.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29129847.s3.e0" e2="DDI-PubMed.29129847.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29129847.s3.e3" e2="DDI-PubMed.29129847.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29129847.s3.e3" e2="DDI-PubMed.29129847.s3.e2" /></sentence><sentence text=" This study aimed to evaluate the inhibitory effect of ketoconazole (KTZ) on CP metabolism through in vitro and in vivo drug-drug interaction (DDI) research"><entity charOffset="55-67" id="DDI-PubMed.29129847.s4.e0" text="ketoconazole" /><entity charOffset="69-72" id="DDI-PubMed.29129847.s4.e1" text="KTZ" /><entity charOffset="77-79" id="DDI-PubMed.29129847.s4.e2" text="CP" /><pair ddi="false" e1="DDI-PubMed.29129847.s4.e0" e2="DDI-PubMed.29129847.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29129847.s4.e0" e2="DDI-PubMed.29129847.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29129847.s4.e0" e2="DDI-PubMed.29129847.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29129847.s4.e1" e2="DDI-PubMed.29129847.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29129847.s4.e1" e2="DDI-PubMed.29129847.s4.e2" /></sentence><sentence text=" Long-term treatment of KTZ induces hepatic injury; thus single doses of KTZ at low, middle, and high levels (10, 20, and 40 mg/kg) were investigated for pharmacokinetic DDI with CP"><entity charOffset="179-180" id="DDI-PubMed.29129847.s5.e0" text="CP" /><entity charOffset="24-25" id="DDI-PubMed.29129847.s5.e1" text="KTZ" /><entity charOffset="73-74" id="DDI-PubMed.29129847.s5.e2" text="KTZ" /><pair ddi="false" e1="DDI-PubMed.29129847.s5.e1" e2="DDI-PubMed.29129847.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29129847.s5.e1" e2="DDI-PubMed.29129847.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29129847.s5.e1" e2="DDI-PubMed.29129847.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29129847.s5.e2" e2="DDI-PubMed.29129847.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29129847.s5.e2" e2="DDI-PubMed.29129847.s5.e0" /></sentence><sentence text=" Our in vitro human liver microsome modeling approach suggested that KTZ inhibited CYP3A4 activity and then decreased DECP exposure"><entity charOffset="120-122" id="DDI-PubMed.29129847.s6.e0" text="CP" /><entity charOffset="118-120" id="DDI-PubMed.29129847.s6.e1" text="DECP" /><entity charOffset="69-71" id="DDI-PubMed.29129847.s6.e2" text="KTZ" /><pair ddi="false" e1="DDI-PubMed.29129847.s6.e2" e2="DDI-PubMed.29129847.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29129847.s6.e2" e2="DDI-PubMed.29129847.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29129847.s6.e2" e2="DDI-PubMed.29129847.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29129847.s6.e1" e2="DDI-PubMed.29129847.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29129847.s6.e1" e2="DDI-PubMed.29129847.s6.e0" /></sentence><sentence text=" In addition, an UHPLC-MS/MS method for quantifying CP, DECP, and KTZ in rat plasma was developed and fully validated with a 4 min analysis coupled with a simple and reproducible one-step protein precipitation"><entity charOffset="52-54" id="DDI-PubMed.29129847.s7.e0" text="CP" /><entity charOffset="58-60" id="DDI-PubMed.29129847.s7.e1" text="CP" /><entity charOffset="56-58" id="DDI-PubMed.29129847.s7.e2" text="DECP" /><entity charOffset="66-68" id="DDI-PubMed.29129847.s7.e3" text="KTZ" /><pair ddi="false" e1="DDI-PubMed.29129847.s7.e0" e2="DDI-PubMed.29129847.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29129847.s7.e0" e2="DDI-PubMed.29129847.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29129847.s7.e0" e2="DDI-PubMed.29129847.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29129847.s7.e0" e2="DDI-PubMed.29129847.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29129847.s7.e2" e2="DDI-PubMed.29129847.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29129847.s7.e2" e2="DDI-PubMed.29129847.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29129847.s7.e2" e2="DDI-PubMed.29129847.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29129847.s7.e1" e2="DDI-PubMed.29129847.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29129847.s7.e1" e2="DDI-PubMed.29129847.s7.e3" /></sentence><sentence text=" A further in vivo pharmacokinetic study demonstrated that combination use of CP (10 mg/kg) and KTZ (10, 20, and 40 mg/kg) in rats caused a KTZ dose-dependent decrease in main parameters of DECP (Cmax, Tmax, and AUC0-âˆž) and provided magnitude exposure of DECP (more than a 50% AUC decrease) as a consequence of CYP3A inhibition but had only a small effect on the CP plasma concentration"><entity charOffset="78-80" id="DDI-PubMed.29129847.s8.e0" text="CP" /><entity charOffset="192-194" id="DDI-PubMed.29129847.s8.e1" text="CP" /><entity charOffset="257-259" id="DDI-PubMed.29129847.s8.e2" text="CP" /><entity charOffset="363-365" id="DDI-PubMed.29129847.s8.e3" text="CP" /><entity charOffset="190-192" id="DDI-PubMed.29129847.s8.e4" text="DECP" /><entity charOffset="255-257" id="DDI-PubMed.29129847.s8.e5" text="DECP" /><entity charOffset="96-98" id="DDI-PubMed.29129847.s8.e6" text="KTZ" /><entity charOffset="140-142" id="DDI-PubMed.29129847.s8.e7" text="KTZ" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e0" e2="DDI-PubMed.29129847.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e0" e2="DDI-PubMed.29129847.s8.e6" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e0" e2="DDI-PubMed.29129847.s8.e7" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e0" e2="DDI-PubMed.29129847.s8.e4" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e0" e2="DDI-PubMed.29129847.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e0" e2="DDI-PubMed.29129847.s8.e5" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e0" e2="DDI-PubMed.29129847.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e0" e2="DDI-PubMed.29129847.s8.e3" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e6" e2="DDI-PubMed.29129847.s8.e6" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e6" e2="DDI-PubMed.29129847.s8.e7" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e6" e2="DDI-PubMed.29129847.s8.e4" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e6" e2="DDI-PubMed.29129847.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e6" e2="DDI-PubMed.29129847.s8.e5" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e6" e2="DDI-PubMed.29129847.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e6" e2="DDI-PubMed.29129847.s8.e3" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e7" e2="DDI-PubMed.29129847.s8.e7" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e7" e2="DDI-PubMed.29129847.s8.e4" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e7" e2="DDI-PubMed.29129847.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e7" e2="DDI-PubMed.29129847.s8.e5" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e7" e2="DDI-PubMed.29129847.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e7" e2="DDI-PubMed.29129847.s8.e3" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e4" e2="DDI-PubMed.29129847.s8.e4" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e4" e2="DDI-PubMed.29129847.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e4" e2="DDI-PubMed.29129847.s8.e5" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e4" e2="DDI-PubMed.29129847.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e4" e2="DDI-PubMed.29129847.s8.e3" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e1" e2="DDI-PubMed.29129847.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e1" e2="DDI-PubMed.29129847.s8.e5" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e1" e2="DDI-PubMed.29129847.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e1" e2="DDI-PubMed.29129847.s8.e3" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e5" e2="DDI-PubMed.29129847.s8.e5" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e5" e2="DDI-PubMed.29129847.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e5" e2="DDI-PubMed.29129847.s8.e3" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e2" e2="DDI-PubMed.29129847.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29129847.s8.e2" e2="DDI-PubMed.29129847.s8.e3" /></sentence><sentence text=" Our results suggested that combination usage of a CYP3A4 inhibitor like KTZ may decrease CAA exposure and thus intervene against CAA-induced adverse effects in CP clinical treatment"><entity charOffset="161-163" id="DDI-PubMed.29129847.s9.e0" text="CP" /><entity charOffset="73-75" id="DDI-PubMed.29129847.s9.e1" text="KTZ" /><pair ddi="false" e1="DDI-PubMed.29129847.s9.e1" e2="DDI-PubMed.29129847.s9.e1" /><pair ddi="true" e1="DDI-PubMed.29129847.s9.e1" e2="DDI-PubMed.29129847.s9.e0" /></sentence><sentence text="" /></document>